Ardigen will be presenting at BioTechX Europe in Basel, 6-8 October, discussing AI-enabled target discovery and phenotypic profiling.
Public source
Publisher name
Public post
One more AI model won't derisk your pipeline if the data and workflow behind it don't hold up. It's one of the topics we'll be talking through at BioTechX Europe in Base…
Company
Ardigen
Artificial Intelligence & Bioinformatics for Precision Medicine
- Industry
- Biotechnology Research
- Location
- Kraków, PL
- Company size
- 51–200 employees
About Ardigen
From complex data to AI-driven drug discovery insights Ardigen is an AI driven data-to-insights partner for life science organizations addressing the complexity of modern, multimodal drug discovery. We build AI-ready biomedical data foundations and reusable data products that support the full drug discovery and development lifecycle, from target identification through clinical and regulatory stages, across diverse therapeutic areas. Our work starts with biology: we align every analytical approach with scientific purpose, enabling our partners to ask better questions, extract more meaningful answers, and move faster from raw data to confident decisions. Whether structuring large-scale omics data, analyzing high-content imaging, or integrating clinical, phenotypic, and chemical profiles, we help drug discovery teams turn fragmented datasets into scalable, insight-driven workflows. What we deliver: - Multimodal data solutions tailored to therapeutic questions - Curated, interoperable data products designed for modeling and experimentation - Custom analytics and AI workflows grounded in scientific relevance Interpretation-ready outputs that accelerate decision-making and reduce R&D risk Why Ardigen: - Deep biological and computational expertise embedded in every solution - Modular delivery model aligned to your data maturity - Proven across 700+ discovery projects - Trusted by global leaders in pharma and biotech Let’s move from data complexity to discovery clarity - together.
See moreDiscover more
Similar signals
Similar public activity from other companies.
Presence & Recognition
Insilico Medicine
Insilico Medicine is hosting an exclusive Pharma AI Q3 Fall Update showcasing Generative Biologics, Chemistry42, and PandaOmics platforms.
Presence & Recognition
Ingenix.ai
Ingenix.ai is co-hosting an evening in Basel on Wednesday, October 7, 5:30–8:30 PM at Acqua alongside Loka, Amazon Web Services (AWS), Outpost Bio and Sofinnova Partners at BioTechX Europe.
Presence & Recognition
Inductive Bio
Inductive Bio is hosting the AI in Drug Discovery Xchange conference in San Francisco on September 9.
Presence & Recognition
DeepLife
DeepLife Head of Drug Discovery Yann Abraham will speak at the Drug Discovery Innovation Programme (DDIP) Europe in Basel on 30 September to discuss Target Identification with Virtual Cells using Large Causal Cell Models in Early Drug Discovery.
Presence & Recognition
Genomics